GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Cyclically Adjusted PB Ratio

Karolinska Development AB (Karolinska Development AB) Cyclically Adjusted PB Ratio : 0.21 (As of May. 17, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Karolinska Development AB Cyclically Adjusted PB Ratio?

As of today (2024-05-17), Karolinska Development AB's current share price is $0.2576. Karolinska Development AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $1.25. Karolinska Development AB's Cyclically Adjusted PB Ratio for today is 0.21.

The historical rank and industry rank for Karolinska Development AB's Cyclically Adjusted PB Ratio or its related term are showing as below:

KDEVF' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.09   Med: 0.16   Max: 0.46
Current: 0.21

During the past years, Karolinska Development AB's highest Cyclically Adjusted PB Ratio was 0.46. The lowest was 0.09. And the median was 0.16.

KDEVF's Cyclically Adjusted PB Ratio is ranked better than
82.13% of 649 companies
in the Biotechnology industry
Industry Median: 1.75 vs KDEVF: 0.21

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Karolinska Development AB's adjusted book value per share data for the three months ended in Mar. 2024 was $0.444. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.25 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Karolinska Development AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Karolinska Development AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB Cyclically Adjusted PB Ratio Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.10 0.33 0.14 0.20

Karolinska Development AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.16 0.17 0.20 0.21

Competitive Comparison of Karolinska Development AB's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Karolinska Development AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karolinska Development AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karolinska Development AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Karolinska Development AB's Cyclically Adjusted PB Ratio falls into.



Karolinska Development AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Karolinska Development AB's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.2576/1.25
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karolinska Development AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Karolinska Development AB's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.444/132.2054*132.2054
=0.444

Current CPI (Mar. 2024) = 132.2054.

Karolinska Development AB Quarterly Data

Book Value per Share CPI Adj_Book
201406 4.802 100.432 6.321
201409 3.790 100.161 5.003
201412 2.745 100.225 3.621
201503 2.762 99.950 3.653
201506 0.800 99.995 1.058
201509 0.735 100.228 0.970
201512 0.486 100.276 0.641
201603 0.296 100.751 0.388
201606 0.160 101.019 0.209
201609 0.116 101.138 0.152
201612 0.054 102.022 0.070
201703 0.132 102.022 0.171
201706 0.074 102.752 0.095
201709 0.458 103.279 0.586
201712 0.440 103.793 0.560
201803 0.413 103.962 0.525
201806 0.434 104.875 0.547
201809 0.437 105.679 0.547
201812 0.452 105.912 0.564
201903 0.412 105.886 0.514
201906 0.418 106.742 0.518
201909 0.384 107.214 0.474
201912 0.539 107.766 0.661
202003 0.452 106.563 0.561
202006 0.479 107.498 0.589
202009 0.407 107.635 0.500
202012 0.483 108.296 0.590
202103 0.458 108.360 0.559
202106 0.596 108.928 0.723
202109 0.579 110.338 0.694
202112 0.539 112.486 0.633
202203 0.504 114.825 0.580
202206 0.472 118.384 0.527
202209 0.418 122.296 0.452
202212 0.443 126.365 0.463
202303 0.429 127.042 0.446
202306 0.426 129.407 0.435
202309 0.417 130.224 0.423
202312 0.450 131.912 0.451
202403 0.444 132.205 0.444

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Karolinska Development AB  (OTCPK:KDEVF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Karolinska Development AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Karolinska Development AB (Karolinska Development AB) Business Description

Traded in Other Exchanges
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.